SCHEMBL663756

SCHEMBL663756

CC(C)(C)c1cc(CN[C@@H]2CCCC[C@H]2NCc2cc(C(C)(C)C)cc(C(C)(C)C)c2O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 6/20 0.59
CYP2D6 P10635 4/20 0.59
CYP1A2 P05177 4/20 0.59
CYP2C9 P11712 4/20 0.59
TSHR P16473 3/20 0.54
ALDH1A1 P00352 3/20 0.51
GAA P10253 3/20 0.51
HTT P42858 2/20 0.51
XBP1 P17861 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
PABPC1 P11940 1/20 0.40
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
TACR1 P25103 1/20 0.38
HSPA5 P11021 2/20 0.37
NR5A2 O00482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL663757 1.00 CYP2C19 (0.59) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL1881392 1.00 CYP2C19 (0.59) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL5673666 1.00 CYP2C19 (0.59) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL30874729 0.99 CYP2C19 (0.58) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL8783194 0.99 CYP2C19 (0.58) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL30505546 0.95 CYP2C19 (0.54) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL10040348 0.94 CYP2C19 (0.56) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL17295969 0.91 CYP2C19 (0.53) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL6057504 0.87 CYP2C19 (0.78) CYP2C19CYP2D6CYP1A2CYP2C9TSHR
SCHEMBL24425958 0.87 CYP2D6 (0.77) CYP2C19CYP2D6CYP1A2CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196175-A1 Hydroxylation of Beta-Dicarbonyls with Zirconium Catalysts FMC CORPORATION 2011-08-11 US claimed
EP-3271344-B1 PROCESS FOR PREPARING AMINOTETRAHYDROPYRANS FIS FABBRICA ITALIANA SINTETICI SPA (IT) 2020-08-26 EP disclosed
US-10377732-B2 Process for preparing aminotetrahydropyrans F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2019-08-13 US disclosed
US-20180290995-A1 Process For Preparing Aminotetrahydropyrans F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2018-10-11 US disclosed
US-8889873-B2 Process for the preparation of enantiomerically enriched proton pump inhibitors LEK PHARMACEUTICALS D.D. (SI) 2014-11-18 US disclosed
US-8889873-B2 Process for the preparation of enantiomerically enriched proton pump inhibitors LEK PHARMACEUTICALS D.D. (SI) 2014-11-18 US disclosed
US-8889873-B2 Process for the preparation of enantiomerically enriched proton pump inhibitors LEK PHARMACEUTICALS D.D. (SI) 2014-11-18 US disclosed
US-8410295-B2 Method for production of optically active epoxy compound, and complex used therefor and process for producing the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-04-02 US disclosed
US-8258345-B2 Hydroxylation of β-dicarbonyls with zirconium catalysts E I DU PONT DE NEMOURS AND COMPANY (US) 2012-09-04 US disclosed
US-20120178954-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND, AND COMPLEX USED THEREFOR AND PROCESS FOR PRODUCING THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2012-07-12 US disclosed
US-20110196175-A1 Hydroxylation of Beta-Dicarbonyls with Zirconium Catalysts FMC CORPORATION 2011-08-11 US disclosed
US-7939685-B2 Hydroxylation of β-dicarbonyls with zirconium catalysts E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-05-10 US disclosed
EP-2264024-A1 Process for the preparation of enantiomerically enriched proton pump inhibitors LEK Pharmaceuticals d.d. (SI) 2010-12-22 EP disclosed
US-20100185014-A1 Hydroxylation of Beta-Dicarbonyls with Zirconium Catalysts FMC CORPORATION 2010-07-22 US disclosed
US-7718818-B2 Hydroxylation of beta-dicarbonyls with zirconium catalysts E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-05-18 US disclosed
WO-2010043601-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS LEK PHARMACEUTICALS D.D. (SI) 2010-04-22 WO disclosed
US-20080306259-A1 HYDROXYLATION OF BETA-DICARBONYLS WITH ZIRCONIUM CATALYSTS FMC CORPORATION 2008-12-11 US disclosed
US-7414157-B2 Hydroxylation of β-dicarbonyls with zirconium catalysts E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-08-19 US disclosed
EP-1401575-B1 HYDROXYLATION OF BETA-DICARBONYLS WITH ZIRCONIUM CATALYSTS DU PONT (US) 2007-01-17 EP disclosed
US-20040143123-A1 Hydroxylation of beta-dicarbonyls with zirconium catalysts FMC CORPORATION 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100185014-A1 Hydroxylation of Beta-Dicarbonyls with Zirconium Catalysts CBR3, CBR1, NOXO1 CYP2C19 337/4885CYP2D6 176/4885CYP1A2 135/4885
US-20040143123-A1 Hydroxylation of beta-dicarbonyls with zirconium catalysts CBR1, CBR3, NOXO1 CYP2C19 429/4885CYP2D6 48/4885CYP1A2 114/4885
US-10377732-B2 Process for preparing aminotetrahydropyrans DPP4, DPP3, DPP9 CYP2C19 193/4885CYP2D6 61/4885CYP1A2 288/4885
US-20110196175-A1 Hydroxylation of Beta-Dicarbonyls with Zirconium Catalysts CBR3, CBR1, NOXO1 CYP2C19 337/4885CYP2D6 176/4885CYP1A2 135/4885
US-20080306259-A1 HYDROXYLATION OF BETA-DICARBONYLS WITH ZIRCONIUM CATALYSTS CBR3, CBR1, ASPH CYP2C19 306/4885CYP2D6 112/4885CYP1A2 123/4885
US-20180290995-A1 Process For Preparing Aminotetrahydropyrans DPP4, DPP3, DPP9 CYP2C19 193/4885CYP2D6 61/4885CYP1A2 288/4885
US-20120178954-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND, AND COMPLEX USED THEREFOR AND PROCESS FOR PRODUCING THE SAME CYP4F11, CYP51A1, COASY CYP2C19 609/4885CYP2D6 341/4885CYP1A2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.